Abstract: Bottom (1) to a container, box, basket, barrel, cask or the like (8) made of a polymeric material and preferably produced by injection moulding. Material thickening and essentially scalloped, jagged and/or wave-like elevations (5) constitute an integrated part of the upper (3) and/or lower (4) surface of the bottom (1). The height (FIG. 12, A-B) of the elevations (5) is 0.5-20 mm representing at least 20% of the maximum thickness of the bottom (1). Intervening spaces (6) are formed between the material thickening elevations (5). A container (8) including a bottom (1) is produced by injection moulding and is cooled in the mould in such a way that the elevations (5) hold a core temperature exceeding the surface temperature to such an extent that the core shrinkage is larger than the surface shrinkage. A strong inner tensile stress is obtained, whereby the elevations (5) work as pretensioned reinforcing bars.

Abstract: A plastic container, basket or the like including a box (2) and a lid (1). The box (2) is made up of a base, four walls (32, 33, 34, 35) and an upper rim (21), which rim (21) in the four upper corners (24, 25, 26, 27) of the box is provided with recesses (28) having vertical surfaces (4) arranged so that an angle (31) of less than 135.degree. is formed on the inside of the box between the surfaces (4) and associated walls (32, 33, 34, 35). The lid (1) consists of four sides (12, 13, 14, 15), four corners (5, 6, 7, 8), an upper surface (18), a lower surface (16) and an outer surrounding border. The four corners (5, 6, 7, 8) have vertical surfaces (3) arranged on the lower surface (16) of the lid that cooperate with the vertical surfaces (4) of the recesses in the rim (21) of the box (2).

Abstract: A hyperbranched macromolecule of polyester type comprising a central monomeric or polymeric nucleus and at least one generation of a branching chain extender having at least three reactive sites of which at least one is a hydroxyl or hydroxyalkyl substituted hydroxyl group and at least one is a carboxyl or terminal epoxide group. The nucleus is an epoxide compound having at least one reactive epoxide group. Optionally, the macromolecule comprises at least one generation consisting of at least one spacing chain extender having two reactive sites of which one is a hydroxyl or hydroxyalkyl substituted hydroxyl group and one is a carboxyl or terminal epoxide group. The macromolecule may be terminated by means of at least one chain stopper.

Abstract: A pharmaceutical composition comprising a pharmaceutically active ingredient selected from the group consisting of trisphosphorylated pentoses, pentitols or anhydropentitols, trisphosphorylated hexoses, hexitols or anhydrohexitols and trisphosphorylated heptoses, heptitols or anhydroheptitols. The active ingredient can also be present in the form of a salt. The invention also includes a method of preventing or alleviating tissue damage in mammals, including man. The method comprises administering an effective amount of the pharmaceutical composition.

Abstract: The invention relates to an inositol phosphate containing pharmaceutical composition which comprises a nitrogen-containing compound for improvement of the bioavailability of the inositol phosphate in mammals including man at non-parenteral administration. The invention also covers the use of at least one nitrogen-containing compound for the preparing of an inositol phosphate containing medicament with improved bioavailibility of inositol phosphate in mammals including man at non-parenteral administration.

Abstract: A cycloaliphatic acrylic monomer having the general formula ##STR1## wherein R.sub.1 is hydrogen, methyl, hydroxyl, HO--(R.sub.3).sub.n or ##STR2## R.sub.2 is ##STR3## R.sub.3 is C.sub.2 H.sub.4 O, C.sub.3 H.sub.6 O, C.sub.4 H.sub.8 O, C.sub.8 H.sub.8 O or mixtures thereof; R.sub.4 is hydrogen or methyl; and n is 1-24. The acrylic monomer is useful as a component in compositions which are radiation curable.

Abstract: A method of preventing or alleviating retroviral disease by administering to a human or a mammal in need thereof a pharmaceutical composition comprising an amount of at least one specific isomer of inositol triphosphate sufficient to obtain said prevention or alleviation.

Abstract: A method of making an acrylate monomer from an essentially ethoxylated polyol, which monomer has a reduced and very low Primary Irritation Index (PII value). The base polyol is di, tri, tetra or polyhydroxyfunctional and the reduced PII value is obtained by reducing the formation of by-products such as monoethylene, diethylene and triethylene glycol during the ethoxylation of the base polyol. A polyol is reacted with propylene oxide at a molar ratio of 1:0.5-1:2.5 and in the presence of an alkali metal hydroxide catalyst. The polyol propoxylate obtained is reacted with ethylene oxide at a molar ratio of 1:2-1:10, whereby an ethoxylated polyol propoxylate with an average molecular weight of 270-500 is obtained. The ethoxylated polyol propoxylate is finally acrylated to yield an acrylate monomer having at least one acrylic unsaturation.